Latest News
Takeda and Orexigen sign $1 billion obesity pact
IMA Institute Self Marketing Workshops
This is a reminder to ALL interim executives that the IMA Institute runs an excellent one-day interactive workshop in London every month! Now, for the first time, the workshops are moving North! October 12th sees our very first workshop in Manchester.
S-A offers $18.5bn for Genzyme
Oxford BioMedica Announces Licensing Agreement with Emergent BioSolutions Inc. -
Oxford BioMedica (“the Company”) (LSE: OXB), a leading gene therapy company, today announces that it has signed a licensing agreement with Emergent Product Development Germany GmbH (“Emergent”), a wholly-owned subsidiary of Emergent BioSolutions Inc.
Cyprotex Adds In Vitro Toxicology Services
Cyprotex PLC (LSE:CRX), the preclinical ADME Tox services company, today announces the launch of its new in vitro toxicology service, branded as Cyprotox(R).
SKYEPHARMA PLC - Appointment of new CEO
Further to the announcement made on 5th May 2010, SkyePharma PLC (LSE:SKP) announces today that it has appointed Dr. Axel Müller as Chief Executive Officer with effect from 23rd August 2010.
CRT Antibody Licence Agreement with Scancell Holdings P
Cancer Research Technology Ltd (‘CRT’) - Cancer Research UK’s commercialisation and development arm, and Scancell Holdings Plc, (AIM:SCLP), the developer of therapeutic cancer vaccines - today announce that they have signed an agreement under which Scancell has been granted a licence to use a human antibody known as 105AD7.
Lumora Secures TSB funding for Point-of-Care Clinical Sample Preparation
Lumora attracts funding of over £100,000 from the Technology Strategy Board (TSB) to support the company’s development of a rapid sample preparation solution for molecular diagnostics at the point of care.
Merck enters Alzheimer's partnership
Gilead discloses manufacturing problems
Sareum raises £200,000
Shire to buy GI company Movetis
Biopharmaceutical company, Shire, plans to extend its portfolio with the purchase of Belgium-based specialist gastrointestinal (GI) company, Movetis, for €428m.